Every material Form 8-K Fulgent Genetics, Inc. has filed with the SEC since June 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Fulgent Genetics reported third quarter 2026 revenue of $90.4 million, up about 8% from a year earlier, but swung to a GAAP loss of $13.2 million, or $(0.48) per share, from a loss of $(0.21) per share a year earlier. The company kept its full-year revenue guidance of $330.0-$340.0 million and improved its outlook for the full-year non-GAAP loss and cash, which it attributed to disciplined spending; the CFO also cited progress on a billing system issue. For shareholders, revenue growth is offset by larger losses in the quarter.
Q3 2026 revenue of $90.4 million versus $84.1 million a year earlier; GAAP loss of $13.2 million, or $(0.48) per share, versus $(0.21) per share
Non-GAAP loss of $2.4 million, or $(0.09) per share, compared with non-GAAP income of $4.5 million, or $0.15 per share, in Q3 2025
Full-year 2026 revenue guidance maintained at $330.0-$340.0 million; non-GAAP loss guidance set at approximately $46.0-$50.0 million
Cash, cash equivalents, restricted cash and marketable securities totaled $652.4 million at September 30, 2026
Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, up from $81.8 million a year earlier, but a GAAP loss of $29.5 million, or $(1.05) per share. The company also lowered its full-year 2026 revenue guidance to $330.0-$340.0 million, which its CFO attributed to processing delays tied to the final phase of a billing system transition. For shareholders, the revenue outlook cut and wider losses weigh against the higher sales.
Q2 2026 revenue was $85.4 million, compared with $81.8 million in Q2 2025.
GAAP loss was $29.5 million, or $(1.05) per share, versus a GAAP loss of $19.0 million, or $(0.62) per share, in Q2 2025.
Non-GAAP loss was $16.2 million, or $(0.58) per share, compared with non-GAAP income of $2.1 million, or $0.07 per share, a year earlier.
Full-year 2026 revenue guidance was revised to $330.0-$340.0 million, and the company bought about 1.5 million shares for $23.8 million in Q2.
Fulgent Genetics said it presented updated preliminary Phase 2 data for its drug candidate FID-007 combined with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma at the ASCO 2026 Annual Meeting. The company reported an objective response rate of 61.9% and median progression-free survival of 6.7 months, and said a Phase 3 study is planned. The filing contains no financial results, so the update concerns the company's therapeutic pipeline rather than current earnings.
Presentation scheduled June 1, 2026, from 4:30 p.m. to 6:00 p.m. CDT in Chicago, as Abstract #6020 at ASCO 2026
Reported objective response rate of 61.9%, median progression-free survival of 6.7 months, and median duration of response of 7.4 months
One-year overall survival of 63.4%, based on data with an April 16, 2026 cutoff from a Phase 2 study (NCT06332092)
A Phase 3 study is planned; slides are to be posted on the investor relations website after the presentation
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Fulgent Genetics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →